Post by icemandios on Dec 4, 2023 14:04:26 GMT
Senhance Robotic System Sold by Asensus Surgical
Senhance® System to be placed at a hospital in the Commonwealth of Independent States
RESEARCH TRIANGLE PARK, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company digitizing the interface between the surgeon and patient, announced that a Senhance® Surgical System has been sold to the Company’s distribution partner and will be placed in a hospital in the Commonwealth of Independent States region. This marks the second system sold to the region in the past month.
The Senhance Surgical System is the only commercially available robotic surgery system with haptic feedback, a differentiating feature for surgeons.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. Based upon the foundations of Digital Laparoscopy and the Senhance Surgical System, the Company is developing the LUNA™ Surgical System, a next generation robotic and instrument system as a foundation of its Digital Surgery solution. These systems will be powered by the Intelligent Surgical Unit™ to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. The Senhance Surgical System is now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. To learn more about Performance-Guided Surgery and digital laparoscopy with the Senhance Surgical System, visit www.asensus.com.